News | RSNA | October 01, 2020

Canon Medical’s Aquilion ONE / PRISM Edition Enables Deep Learning Spectral Capabilities

Canon Medical’s Aquilion ONE / PRISM Edition, designed for deep intelligence, integrates artificial intelligence (AI) technology to maximize conventional and spectral computed tomography (CT) capabilities with automated workflows, while providing deep clinical insights to assist physicians in making more informed decisions across the patient’s care cycle.

October 1, 2020 — Canon Medical’s Aquilion ONE / PRISM Edition, designed for deep intelligence, integrates artificial intelligence (AI) technology to maximize conventional and spectral computed tomography (CT) capabilities with automated workflows, while providing deep clinical insights to assist physicians in making more informed decisions across the patient’s care cycle. The system comes equipped with Advanced intelligent Clear-IQ Engine (AiCE), an innovative approach to CT reconstruction that uses deep learning to distinguish true signal from noise to deliver sharp, clear and distinct images at fast speeds. More information is available here and at Canon Medical’s unique, immersive virtual booth experience during RSNA 2020.

For more information: www.us.medical.canon

Related Content

Owkin, a startup that deploys artificial intelligence (AI) and Federated Learning technologies to augment medical research and enable scientific discoveries, presented findings in Hepatocellular Carcinoma (HCC) with Cleveland Clinic at the 2021 European Society of Medical Oncology (ESMO) conference.

Illustration courtesy of Cleveland Clinic

News | Artificial Intelligence | September 24, 2021

Owkin and Cleveland Clinic Develop AI Model that Predicts Liver Cancer Prognosis

September 24, 2021 — Owkin, a startup that deploys...

Doctors say they should be making medical decisions with patients, not insurance carriers and outline principles for noninvasive testing

News | Cardiac Imaging | September 23, 2021

Cardiovascular Imaging Organizations Denounce Test Substitution by Insurance Companies

September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by

GE has entered into an agreement to acquire BK Medical, a leader in advanced surgical visualization, from Altaris Capital Partners for a cash purchase price of $1.45 billion.

Getty Images

News | Radiology Business | September 23, 2021

GE Healthcare to Acquire BK Medical and Expand Ultrasound Portfolio

September 23, 2021 — GE has entered into an

Paige Prostate, is the first artificial intelligence (AI)-based software designed to identify an area of interest on the prostate biopsy image with the highest likelihood of harboring cancer so it can be reviewed further by the pathologist if the area of concern has not been identified on initial review.

News | Digital Pathology | September 22, 2021

FDA Authorizes Software That Can Help Identify Prostate Cancer

September 22, 2021 — The U.S.

This study shows that thanks to deep learning analysis applied to digitized pathology slides, artificial intelligence can classify patients with localized breast cancer between high risk and low risk of metastatic relapse in the next five years.

Getty Images

News | Artificial Intelligence | September 22, 2021

AI Predicts Risk of Breast Cancer Recurrence for Women

September 22, 2021 — The RACE AI study conducted by Gustave...

The development of new research guidelines for interventional oncology that standardize treatment outcomes and the reporting of data represents a major step forward for an increasingly important medical subspecialty, according to a report in Radiology.

Getty Images

News | Radiation Oncology | September 21, 2021

New Research Guidelines Will Boost Interventional Oncology Research

September 21, 2021 — The development of new research guidelines for interventional oncology that standardize treatmen

HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed research recently published in the journal Cancers has demonstrated the ability of its radiomics technology to identify biomarkers that predict whether patients with lung adenocarcinoma would benefit from immunotherapy.

Semi-automatic lesion identification: (A) Manual ROI indication. In blue, it is possible to observe the axes that cross the lesion manually delineated by the radiologist on a plane of the MPR. The intensity of the lesion boundary (estimated) is represented with a red outline. (B) Additional axes can be dragged onto other orthogonal MPR views. From left to right, it is possible to observe the initial long axis outlined by the radiologist and the 2D contours on the axial, coronal and sagittal views of the lesion used as a starting point for the RPM algorithms. (C) Resulting 3D contour of the lesion (in blue).

News | Radiomics | September 21, 2021

HealthMyne’s Radiomic Technology Leveraged to Identify Biomarkers That Predict Immunotherapy Treatment Responses

September 21, 2021 — HealthMyne, a pioneer in applied radiomics, announced today that peer-reviewed ...